| 2-(2, 4, 5-substituted-anilino) pyrimidine compounds S Butterworth, MRV Finlay, RA Ward, HM Redfearn, VK Kadambar, ... US Patent App. 18/406,693, 2024 | | 2024 |
| Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations C Thomson, P Barton, E Braybrooke, N Colclough, Z Dong, L Evans, ... Journal of Medicinal Chemistry, 2024 | | 2024 |
| Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR N Pemberton, N Compagne, A Argyrou, E Evertsson, A Gunnarsson, ... ACS Medicinal Chemistry Letters 15 (5), 583-589, 2024 | | 2024 |
| Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release PA Morese, N Anthony, M Bodnarchuk, C Jennings, MP Martin, RA Noble, ... Journal of Medicinal Chemistry 66 (17), 12324-12341, 2023 | 2 | 2023 |
| 2-(2, 4, 5-substituted-anilino) pyrimidine compounds S Butterworth, MRV Finlay, RA Ward, HM Redfearn, VK Kadambar, ... US Patent 11,524,951, 2022 | 1 | 2022 |
| 2-(2, 4, 5-substituted-anilino) pyrimidine compounds as egfr modulators S Butterworth, RA Ward, MRV Finlay, VK Kadambar, CR Chintakuntla, ... | | 2022 |
| 2-(2, 4, 5-substituoitu-anilino) pyrimidiiniyhdisteitä S Butterworth, RA Ward, MRV Finlay, V Kadambar, C Chintakuntla, ... | | 2022 |
| 2-(2, 4, 5-pakeistieji-anilino) pirimidino junginiai S Butterworth, RA Ward, MRV Finlay, V Kadambar, C Chintakuntla, ... | | 2021 |
| Generation of quantum configurational ensembles using approximate potentials J Morado, PN Mortenson, JWM Nissink, ML Verdonk, RA Ward, JW Essex, ... Journal of Chemical Theory and Computation 17 (11), 7021-7042, 2021 | 4 | 2021 |
| Potent and selective inhibitors of the epidermal growth factor receptor to overcome C797S-mediated resistance MRV Finlay, P Barton, S Bickerton, M Bista, N Colclough, DAE Cross, ... Journal of medicinal chemistry 64 (18), 13704-13718, 2021 | 16 | 2021 |
| Structural basis of the effect of activating mutations on the EGF receptor I Galdadas, L Carlino, RA Ward, SJ Hughes, S Haider, FL Gervasio Elife 10, e65824, 2021 | 27 | 2021 |
| The design of covalent-based inhibitors RA Ward, N Grimster Academic Press, 2021 | 4 | 2021 |
| Paramol: A package for automatic parameterization of molecular mechanics force fields J Morado, PN Mortenson, ML Verdonk, RA Ward, JW Essex, CK Skylaris Journal of Chemical Information and Modeling 61 (4), 2026-2047, 2021 | 33 | 2021 |
| AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor … V Flemington, EJ Davies, D Robinson, LC Sandin, O Delpuech, P Zhang, ... Molecular cancer therapeutics 20 (2), 238-249, 2021 | 16 | 2021 |
| compostos de fórmula (i), composição farmacêutica e uso do composto S Butterworth, MRV Finlay, RA Ward, VK Kadambar, CR Chintakuntla, ... | | 2021 |
| Structural basis of the effect of activating mutations on the EGF receptor G Ioannis, C Luca, RA Ward, SJ Hughes, H Shozeb, FL Gervasio eLife 10, 2021 | | 2021 |
| Drugging the undruggable: a computational chemist's view of KRAS G12C MS Bodnarchuk, DJ Cassar, JG Kettle, G Robb, RA Ward RSC Medicinal Chemistry 12 (4), 609-614, 2021 | 2 | 2021 |
| Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs N Colclough, K Chen, P Johnström, N Strittmatter, Y Yan, GL Wrigley, ... Clinical Cancer Research 27 (1), 189-201, 2021 | 138 | 2021 |
| Modeling Covalent Protein-Ligand Interactions RA Ward Academic Press, 2021 | | 2021 |
| 2-(2, 4, 5-substituted-anilino) pyrimidine compounds S Butterworth, MRV Finlay, RA Ward, HM Redfearn, VK Kadambar, ... US Patent 10,858,336, 2020 | | 2020 |
